Hubei Hongyuan Pharmaceutical Technology Balance Sheet Health
Financial Health criteria checks 5/6
Hubei Hongyuan Pharmaceutical Technology has a total shareholder equity of CN¥4.3B and total debt of CN¥362.4M, which brings its debt-to-equity ratio to 8.3%. Its total assets and total liabilities are CN¥5.9B and CN¥1.5B respectively. Hubei Hongyuan Pharmaceutical Technology's EBIT is CN¥132.4K making its interest coverage ratio -0. It has cash and short-term investments of CN¥1.7B.
Key information
8.3%
Debt to equity ratio
CN¥362.39m
Debt
| Interest coverage ratio | -0.006x |
| Cash | CN¥1.69b |
| Equity | CN¥4.35b |
| Total liabilities | CN¥1.51b |
| Total assets | CN¥5.86b |
Recent financial health updates
No updates
Recent updates
Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%
Oct 08
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable
Aug 23Hubei Hongyuan Pharmaceutical Technology's (SZSE:301246) Soft Earnings Are Actually Better Than They Appear
Apr 29Getting In Cheap On Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) Is Unlikely
Mar 14Financial Position Analysis
Short Term Liabilities: 301246's short term assets (CN¥3.0B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 301246's short term assets (CN¥3.0B) exceed its long term liabilities (CN¥331.3M).
Debt to Equity History and Analysis
Debt Level: 301246 has more cash than its total debt.
Reducing Debt: 301246's debt to equity ratio has reduced from 25.9% to 8.3% over the past 5 years.
Debt Coverage: 301246's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 301246 earns more interest than it pays, so coverage of interest payments is not a concern.